We only have this paper's title and publication details.
Read it at the sourceLiterature review demonstrates rapid efficacy and oral convenience of Janus kinase inhibitors in inflammatory diseases, highlighting unresolved thromboembolic and malignancy safety risks.
No takes yet. Share an insight, caveat, or question.
Doktorova et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: